IDEAS home Printed from https://ideas.repec.org/a/bla/biomet/v66y2010i2p532-540.html
   My bibliography  Save this article

Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Author

Listed:
  • Nadine Houede
  • Peter F. Thall
  • Hoang Nguyen
  • Xavier Paoletti
  • Andrew Kramar

Abstract

No abstract is available for this item.

Suggested Citation

  • Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
  • Handle: RePEc:bla:biomet:v:66:y:2010:i:2:p:532-540
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1111/j.1541-0420.2009.01302.x
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Z. Yuan & R. Chappell & H. Bailey, 2007. "The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi-Likelihood Approach," Biometrics, The International Biometric Society, vol. 63(1), pages 173-179, March.
    2. Bekele, B. Nebiyou & Thall, Peter F., 2004. "Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial," Journal of the American Statistical Association, American Statistical Association, vol. 99, pages 26-35, January.
    3. Peter F. Thall & John D. Cook, 2004. "Dose-Finding Based on Efficacy–Toxicity Trade-Offs," Biometrics, The International Biometric Society, vol. 60(3), pages 684-693, September.
    4. Ying Kuen Cheung & Rick Chappell, 2000. "Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities," Biometrics, The International Biometric Society, vol. 56(4), pages 1177-1182, December.
    5. Peter F. Thall & Hoang Q. Nguyen & Elihu H. Estey, 2008. "Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates," Biometrics, The International Biometric Society, vol. 64(4), pages 1126-1136, December.
    6. Peter F. Thall & Randall E. Millikan & Peter Mueller & Sang-Joon Lee, 2003. "Dose-Finding with Two Agents in Phase I Oncology Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 487-496, September.
    7. Anastasia Ivanova, 2003. "A New Dose-Finding Design for Bivariate Outcomes," Biometrics, The International Biometric Society, vol. 59(4), pages 1001-1007, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Drovandi, Christopher C. & McGree, James M. & Pettitt, Anthony N., 2013. "Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data," Computational Statistics & Data Analysis, Elsevier, vol. 57(1), pages 320-335.
    2. Beibei Guo & Elizabeth Garrett‐Mayer & Suyu Liu, 2021. "A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(5), pages 1210-1229, November.
    3. Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
    4. Thomas A. Murray & Ying Yuan & Peter F. Thall & Joan H. Elizondo & Wayne L. Hofstetter, 2018. "A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups," Biometrics, The International Biometric Society, vol. 74(3), pages 1095-1103, September.
    5. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    6. Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anastasia Ivanova & Se Hee Kim, 2009. "Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach," Biometrics, The International Biometric Society, vol. 65(1), pages 307-315, March.
    2. B. Nebiyou Bekele & Yisheng Li & Yuan Ji, 2010. "Risk-Group-Specific Dose Finding Based on an Average Toxicity Score," Biometrics, The International Biometric Society, vol. 66(2), pages 541-548, June.
    3. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    4. Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.
    5. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    6. Yifei Zhang & Sha Cao & Chi Zhang & Ick Hoon Jin & Yong Zang, 2021. "A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes," Biometrics, The International Biometric Society, vol. 77(3), pages 796-808, September.
    7. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    8. Sergei Leonov & Bahjat Qaqish, 2020. "Correlated endpoints: simulation, modeling, and extreme correlations," Statistical Papers, Springer, vol. 61(2), pages 741-766, April.
    9. Xiaobin Yang & Keying Ye, 2012. "A Phase I Dose-_finding Study Based on Polychotomous Toxicity Responses Toxicity issue is always a main concern in phase I study and it is commonly categorized to multiple grades. In this study, the c," Working Papers 0004, College of Business, University of Texas at San Antonio.
    10. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    11. Beibei Guo & Ying Yuan, 2017. "Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents," Journal of the American Statistical Association, Taylor & Francis Journals, vol. 112(518), pages 508-520, April.
    12. Guosheng Yin & Ying Yuan, 2009. "A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents," Biometrics, The International Biometric Society, vol. 65(3), pages 866-875, September.
    13. Alam, M. Iftakhar & Bogacka, Barbara & Coad, D. Stephen, 2017. "Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials," Computational Statistics & Data Analysis, Elsevier, vol. 111(C), pages 183-202.
    14. Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
    15. Shenghua Fan & Bee Leng Lee & Ying Lu, 2020. "A Curve-Free Bayesian Decision-Theoretic Design for Phase Ia/Ib Trials Considering Both Safety and Efficacy Outcomes," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 12(2), pages 146-166, July.
    16. Guosheng Yin & Yisheng Li & Yuan Ji, 2006. "Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios," Biometrics, The International Biometric Society, vol. 62(3), pages 777-787, September.
    17. Peter F. Thall & Hoang Q. Nguyen & Elihu H. Estey, 2008. "Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates," Biometrics, The International Biometric Society, vol. 64(4), pages 1126-1136, December.
    18. Peter F. Thall & Hoang Q. Nguyen & Thomas M. Braun & Muzaffar H. Qazilbash, 2013. "Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes," Biometrics, The International Biometric Society, vol. 69(3), pages 673-682, September.
    19. Erica Brittain & Dean Follmann & Song Yang, 2008. "Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long-Term Binary Endpoint," Biometrics, The International Biometric Society, vol. 64(1), pages 189-197, March.
    20. Thomas M. Braun, 2018. "Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals," Biometrics, The International Biometric Society, vol. 74(3), pages 1065-1071, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:biomet:v:66:y:2010:i:2:p:532-540. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0006-341X .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.